Website survey

We want your feedback on the Scottish Parliament website. Take our 6 question survey now

Skip to main content

Language: English / GĂ idhlig


Chamber and committees

Question ref. S6W-02332
Asked by: Beatrice Wishart, Shetland Islands, Scottish Liberal Democrats
Date lodged: 18 August 2021


To ask the Scottish Government what discussions it has had with Gilead Sciences, which is a manufacturer of sacituzumab govitecan, also known as Trodelvy, to ensure that patients in Scotland are able to access this drug for the treatment of triple-negative breast cancer (TNBC).

Current status: Answered by Humza Yousaf on 30 September 2021


Scottish Government officials have had informal discussions with the manufacturer, Gilead Sciences, to provide early access to sacituzumab govitecan (Trodelvy ® ) on an individual patient case by case basis in line with standard processes for such circumstances before it is submitted to the Scottish Medicines Consortium for health technology assessment.